Choose a module

70 medications

Explore Featured Medication Modules

NaV1.8 inhibitorAcute painNaV1.8

suzetrigine

Journavx

Moderate-to-severe acute pain

Approval: Jan 30, 2025Sponsor: Vertex
AntibioticAvailable NowAnti-infective

gepotidacin

Blujepa

Uncomplicated urinary tract infections and uncomplicated urogenital gonorrhea

Approval: Mar 25, 2025Sponsor: GSK
PCSK9 inhibitorCardiology

lerodalcibep-liga

Lerochol

Hypercholesterolemia, including HeFH

Approval: Dec 12, 2025Sponsor: LIB Therapeutics
Anti-infective

ensitrelvir

Xocova

COVID-19 post-exposure prophylaxis

Approval: May 29, 2026Sponsor: Shionogi
Anti-infective

clesrovimab-cfor

Enflonsia

Prevention of RSV lower respiratory tract disease in neonates and infants entering their first RSV season

Approval: Jun 9, 2025Sponsor: Merck
Anti-infective

doravirine and islatravir

Idvynso

Replacement regimen for virologically suppressed adults with HIV-1

Approval: Apr 20, 2026Sponsor: Merck Sharp & Dohme
PCSK9 inhibitorCardiology

enlicitide

Lipfendra

LDL-C reduction in adults with hypercholesterolemia, including HeFH

Approval: Jul 2026Sponsor: Merck
NMDA receptor antagonistPipeline

esketamine hydrochloride

Spravato

Treatment-resistant depression eligibility screening

Sponsor: Janssen

Available Resources

Full catalog locked

We couldn’t check your sign-in. Try again, or sign in to browse the full catalog.